Please login to the form below
Rybelsus
This page shows the latest Rybelsus news and features for those working in and with pharma, biotech and healthcare.
Lilly’s Trulicity scores CV reduction indication in the US
Novo also has Rybelsus – oral semaglutide – in its arsenal, and analysts at Pareto Securities have suggested that demand for an oral alternative GLP-1 could make the drug a $5.4bn
Latest news
-
New drugs drive Novo Nordisk despite insulin price pressures
Novo also reported sales of DKK50m for its recently launched oral semaglutide product Rybelsus in the quarter – the company has said it is encouraged by the early performance of the drug, ... The Rybelsus launch in the US is off to a good start, and
-
Givlaari, Rybelsus lead crowded CHMP recommendations
Joining Givlaari with a positive recommendation was Rybelsus (semaglutide), Novo Nordisk’s once-daily oral formulation of its injectable GLP-1 agonist semaglutide. ... In Novo’s Pioneer programme of the drug, people treated with Rybelsus achieved
-
Novo Nordisk gets MACE prevention claim for Ozempic in US
Otherwise, it is also conducting a dedicated cardiovascular outcomes trial for Rybelsus – SOUL – that is due to generate data in 2024. ... Some market predictors think Rybelsus could go even higher if the SOUL data is competitive.
-
Novo bolstered by new diabetes, obesity products
Also helping to bolster its sales and growth is new oral semaglutide drug Rybelsus, which received approval from the FDA in the US recently. ... Lars Fruergaard Jørgensen, president and CEO of Novo Nordisk. "During the third quarter of 2019, we have
-
Novo Nordisk gets FDA okay for new diabetes hope
product. The US regulator has approved the Danish drugmaker’s oral formulation of semaglutide under the Rybelsus brand name, extending its range of GLP-1 agonist drugs that include once-weekly ... Rybelsus will be launched in the US in the fourth
More from news
Approximately 3 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
7. NovoNordisk’s Rybelsus is an oral once-daily formulation of semaglutide, a long-acting glucagon-like peptide (GLP)-1 analog. ... Rybelsus is available in the US to improve glycaemic control in adults with type 2 diabetes.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- FDA approves Roche’s Actemra COVID-19 trial
- Roche’s Ocrevus boasts positive long-term data in MS
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Valid Insight
Valid Insight is an award-winning pharmaceutical global market access consultancy....
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
